Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer

Background: Immunotherapy (IT) has led to improved survival in several common cancers but success in pancreatic ductal adenocarcinoma (PDAC) has been limited. We analyzed if combination IT–chemotherapy (IT-CT) is associated with improved survival compared with chemotherapy alone (CT) in patients wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Pancreat Cancer
Hlavní autoři: Hue, Jonathan J., Bingmer, Katherine, Sugumar, Kavin, Markt, Sarah C., Rothermel, Luke D., Hardacre, Jeffrey M., Ammori, John B., Winter, Jordan M., Ocuin, Lee M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc., publishers 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080907/
https://ncbi.nlm.nih.gov/pubmed/33937617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pancan.2021.0003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky